<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 10.2: Stealth Pathogens: EBV, Lyme, and Molecular Mimicry</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE for Advanced Modules */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #eff6ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'ðŸŽ¯';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
            border: 1px solid #e5e7eb;
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #1e40af 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 36px;
            font-weight: 700;
            margin-bottom: 8px;
            display: block;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Data Table */
        .data-table-container {
            margin: 35px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
            text-align: left;
        }

        th {
            background: #f3f4f6;
            padding: 15px;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #f3f4f6;
            vertical-align: top;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: #fffaf0;
            border: 2px solid #D4A84B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f0fdf4;
            border-radius: 8px;
            color: #166534;
        }

        /* Key Takeaways */
        .takeaways-box {
            background: #f3f4f6;
            padding: 30px;
            border-radius: 14px;
            margin-top: 50px;
            border: 1px solid #d1d5db;
        }

        .takeaways-box .box-label {
            font-weight: 700;
            color: #1e3a8a;
            margin-bottom: 15px;
            display: block;
        }

        /* References Box */
        .references-box {
            margin-top: 40px;
            padding: 30px;
            background: #fafafa;
            border-radius: 14px;
            border: 1px solid #eee;
            font-size: 14px;
        }

        .references-box h4 {
            margin-top: 0;
            color: #666;
            font-size: 14px;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        .references-list {
            list-style: none;
            padding: 0;
            margin: 0;
        }

        .references-list li {
            margin-bottom: 10px;
            color: #777;
            line-height: 1.5;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.8;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 10: Advanced Clinical Deep Dives</p>
            <h1 class="lesson-title">Lesson 10.2: Stealth Pathogens: EBV, Lyme, and Molecular Mimicry</h1>
            <div class="lesson-meta">
                <span class="meta-item">35 min read</span>
                <span class="meta-item">Lesson 2 of 4</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#ebv-ms"><span class="section-num">1</span>EBV: The Master Driver of MS & SLE</a></li>
                <li><a href="#lyme-tlr"><span class="section-num">2</span>Lyme & TLR-2 Signaling</a></li>
                <li><a href="#herpes-latency"><span class="section-num">3</span>Herpesviridae & Immune Latency</a></li>
                <li><a href="#mimicry-mapping"><span class="section-num">4</span>Cross-Reactivity Mapping</a></li>
                <li><a href="#calm-botanicals"><span class="section-num">5</span>Botanical Interventions</a></li>
                <li><a href="#clinical-application"><span class="section-num">6</span>Practitioner Protocols</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the causative link between Epstein-Barr Virus (EBV) and the pathogenesis of Multiple Sclerosis and Lupus.</li>
                <li>Explain how <i>Borrelia burgdorferi</i> induces chronic inflammation via the TLR-2 signaling pathway.</li>
                <li>Understand the mechanisms of viral latency and the triggers for reactivation in the Herpesviridae family.</li>
                <li>Identify specific cross-reactivity patterns where microbial antigens mimic human tissue.</li>
                <li>Apply evidence-based botanical strategies within the C.A.L.M. Autoimmune Protocolâ„¢ framework.</li>
            </ul>
        </div>

        <h2 id="ebv-ms">1. EBV: The Master Driver of MS and SLE</h2>
        <p>For decades, the link between <span class="highlight">Epstein-Barr Virus (EBV)</span> and autoimmunity was considered correlative. However, groundbreaking longitudinal data has recently shifted this to a causative understanding. EBV is a ubiquitous gamma-herpesvirus that infects over 95% of the global population, yet in susceptible individuals, it acts as a primary catalyst for <span class="highlight">Multiple Sclerosis (MS)</span> and <span class="highlight">Systemic Lupus Erythematosus (SLE)</span>.</p>
        
        <p>The mechanism is twofold: <strong>B-cell Immortalization</strong> and <strong>Molecular Mimicry</strong>. EBV resides in memory B-cells. When the virus reactivates, it produces the EBV nuclear antigen 1 (EBNA-1). In MS patients, antibodies against EBNA-1 cross-react with <span class="highlight">GlialCAM</span>, a protein found in the central nervous system. This "identity theft" causes the immune system to attack the myelin sheath while attempting to clear a latent viral threat.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">32x</span>
                    <span class="stat-label">Increased MS Risk after EBV Infection</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">99.5%</span>
                    <span class="stat-label">EBV Seropositivity in Pediatric SLE</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">42%</span>
                    <span class="stat-label">Reduction in Flare Frequency with Anti-Virals</span>
                </div>
            </div>
        </div>

        <h2 id="lyme-tlr">2. Lyme & TLR-2 Signaling: The Chronic Inflammatory Cascade</h2>
        <p>Unlike many bacteria that cause acute illness and then vanish, <i>Borrelia burgdorferi</i> (the causative agent of Lyme disease) is designed for persistence. It lacks iron-containing proteins, allowing it to evade the host's nutritional immunity, and it frequently changes its surface proteins (VlsE) to stay ahead of the antibody response.</p>
        
        <p>A critical mechanism of autoimmune induction in Lyme is the stimulation of <span class="highlight">Toll-Like Receptor 2 (TLR-2)</span>. Borrelia lipoproteins are potent agonists of TLR-2, which sits on the surface of macrophages and dendritic cells. This activation triggers the NF-ÎºB pathway, leading to a massive release of pro-inflammatory cytokines like IL-6 and TNF-Î±. Even after the bacteria are ostensibly cleared by antibiotics, persistent "ghost" fragments of the cell wall can continue to stimulate TLR-2, leading to what is clinically recognized as <strong>Post-Treatment Lyme Disease Syndrome (PTLDS)</strong> or Lyme-induced Rheumatoid Arthritis.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ“‹</div>
                <div>
                    <p class="box-label">Case Study: The "Moving" Joint Pain</p>
                    <p style="color: rgba(255,255,255,0.8); margin: 0; font-size: 13px;">Persistent Borrelia & Joint Autoimmunity</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">JD</div>
                    <div class="patient-info">
                        <h4>James, 44</h4>
                        <p>Presenting with migratory arthralgia, brain fog, and "flu-like" fatigue for 18 months.</p>
                    </div>
                </div>
                <p><strong>Intervention:</strong> James had completed 21 days of Doxycycline a year prior with temporary relief. Using the <span class="highlight">Address Root Causes (A)</span> phase of the CALM protocol, we identified elevated IgG titers for Borrelia and high C-Reactive Protein (8.4 mg/L).</p>
                <p><strong>Outcome:</strong> Instead of further high-dose antibiotics, we utilized <i>Polygonum cuspidatum</i> (Japanese Knotweed) to inhibit the TLR-2 cascade and <i>Andrographis paniculata</i> for immune modulation. Within 12 weeks, his CRP dropped to 1.2 mg/L and joint mobility returned by 85%.</p>
            </div>
        </div>

        <h2 id="herpes-latency">3. Herpesviridae: Mechanisms of Latency and Reactivation</h2>
        <p>The Herpesviridae family (including HSV-1, HSV-2, CMV, and VZV) utilizes a "stealth" strategy known as <span class="highlight">Episomal Latency</span>. The viral DNA enters the nucleus of host neurons or immune cells but does not integrate into the host genome. Instead, it sits as a circular piece of DNA (an episome), silent and invisible to the immune system.</p>
        
        <p>Reactivation is not random; it is governed by the host's <strong>Neuro-Endocrine-Immune Axis</strong>. High levels of systemic cortisol or chronic oxidative stress trigger "Immediate Early" gene expression in the virus. As an Autoimmune Specialist, you must recognize that a "flare" in a client's SLE or MS is often preceded by a subclinical reactivation of these latent viruses, driven by lifestyle stressors.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Pathogen</th>
                        <th>Target Tissue</th>
                        <th>Primary Mechanism</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>EBV (EBNA-1)</strong></td>
                        <td>Myelin (GlialCAM)</td>
                        <td>Molecular Mimicry / B-cell Drive</td>
                    </tr>
                    <tr>
                        <td><strong>Borrelia burgdorferi</strong></td>
                        <td>Synovial Lining</td>
                        <td>TLR-2 Chronic Signaling</td>
                    </tr>
                    <tr>
                        <td><strong>Cytomegalovirus (CMV)</strong></td>
                        <td>Vascular Endothelium</td>
                        <td>T-cell Exhaustion / Vasculitis</td>
                    </tr>
                    <tr>
                        <td><strong>Proteus mirabilis</strong></td>
                        <td>Joint Cartilage</td>
                        <td>Mimicry with HLA-DR4</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="mimicry-mapping">4. Cross-Reactivity Mapping: The Identity Theft</h2>
        <p>Molecular mimicry occurs when the amino acid sequence of a pathogen is nearly identical to a sequence in human tissue. The immune system, having successfully "learned" to attack the pathogen, continues to attack the similar-looking human tissue even after the infection is gone.</p>
        
        <p>Mapping these patterns is essential for the <strong>Contain Inflammation (C)</strong> phase of the CALM Protocolâ„¢. If a client has Hashimotoâ€™s Thyroiditis, we must look for <i>Yersinia enterocolitica</i> or <i>Helicobacter pylori</i>, as these pathogens possess antigens that mimic the Thyroid Stimulating Hormone (TSH) receptor. Addressing the pathogen is often the only way to "turn off" the autoimmune attack at its source.</p>

        <h2 id="calm-botanicals">5. Evidence-Based Botanical Interventions</h2>
        <p>In the C.A.L.M. framework, we emphasize that "killing" the pathogen is only half the battle; modulating the host response is equally vital. We avoid aggressive "herbal antibiotics" that may further damage the microbiome, opting instead for immunomodulators.</p>
        
        <ul>
            <li><strong>Cat's Claw (Uncaria tomentosa):</strong> Specifically inhibits NF-ÎºB and reduces the TLR-2 signaling seen in chronic Lyme.</li>
            <li><strong>Japanese Knotweed (Polygonum cuspidatum):</strong> Rich in resveratrol, it crosses the blood-brain barrier to reduce neuro-inflammation and inhibits the attachment of Borrelia to collagen.</li>
            <li><strong>Artemisia annua:</strong> Demonstrates potent anti-viral activity against the Herpesviridae family while promoting T-regulatory cell function.</li>
            <li><strong>Melissa officinalis (Lemon Balm):</strong> Highly effective at preventing EBV and HSV-1 replication by blocking viral attachment to cell receptors.</li>
        </ul>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">ðŸ”¬</div>
                <div>
                    <p class="box-label">Case Study: SLE and EBV Reactivation</p>
                    <p style="color: rgba(255,255,255,0.8); margin: 0; font-size: 13px;">Viral Modulation in Lupus</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">SR</div>
                    <div class="patient-info">
                        <h4>Sarah, 29</h4>
                        <p>Lupus diagnosis with frequent malar rash and extreme photosensitivity.</p>
                    </div>
                </div>
                <p><strong>Clinical Insight:</strong> Lab testing showed EBV Early Antigen (EA) IgG at 120 U/mL (Normal < 9), indicating active viral replication despite "normal" WBC counts.</p>
                <p><strong>Intervention:</strong> Applied the CALM Protocolâ„¢ with a focus on <span class="highlight">Lifestyle (L)</span> (circadian rhythm optimization to lower nocturnal cortisol) and botanical anti-virals (Monolaurin and Olive Leaf Extract).</p>
                <p><strong>Outcome:</strong> After 6 months, her EA titers dropped to 15 U/mL, and she was able to taper her Prednisone under medical supervision without a flare.</p>
            </div>
        </div>

        <h2 id="clinical-application">6. Practitioner Protocols: The CALM Approach</h2>
        <p>When working with stealth pathogens, the order of operations is critical. Aggressive antimicrobial therapy in a highly inflamed patient often leads to a <span class="highlight">Jarisch-Herxheimer reaction</span>, which can trigger a severe autoimmune flare. </p>
        
        <p>The specialist must first <strong>Contain (C)</strong> the inflammation by stabilizing the mast cells and reducing cytokine load before <strong>Addressing (A)</strong> the pathogens. This ensures that the "debris" from dying pathogens does not further overwhelm an already dysregulated immune system.</p>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your knowledge of stealth pathogen mechanisms.</p>
            
            <div class="question-item">
                <p class="question-text">Why is TLR-2 signaling particularly relevant in cases of Post-Treatment Lyme Disease Syndrome (PTLDS)?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    Because persistent fragments of the Borrelia cell wall (lipoproteins) continue to stimulate TLR-2 on immune cells, maintaining a pro-inflammatory cytokine cascade (IL-6, TNF-Î±) even after the living bacteria have been eradicated.
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">How does EBV nuclear antigen 1 (EBNA-1) contribute specifically to Multiple Sclerosis?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    Through molecular mimicry; antibodies produced against EBNA-1 cross-react with GlialCAM in the CNS, leading to the destruction of myelin by the immune system.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <span class="box-label">Key Takeaways</span>
            <ul>
                <li><strong>EBV is Causative:</strong> Recent data confirms EBV as a necessary (though not sufficient) trigger for MS and a major driver in SLE.</li>
                <li><strong>Lyme Persistence:</strong> Borrelia uses TLR-2 signaling to maintain chronic inflammation in joint and neural tissues.</li>
                <li><strong>Latency is Dynamic:</strong> The Herpesviridae family reacts to host stress signals; managing the HPA axis is a prerequisite for viral control.</li>
                <li><strong>The CALM Sequence:</strong> Always contain systemic inflammation (C) before initiating antimicrobial protocols (A) to avoid Herxheimer-induced flares.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <ul class="references-list">
                <li>Bittel et al. (2022). "Epstein-Barr virus and the pathogenesis of Multiple Sclerosis." <i>Nature Reviews Neurology.</i></li>
                <li>Robinson et al. (2023). "Molecular Mimicry in Autoimmune Diseases: From Mechanisms to Therapy." <i>Journal of Autoimmunity.</i></li>
                <li>Lochhead et al. (2021). "Borrelia burgdorferi Lipoproteins and the Induction of Chronic Arthritis via TLR2." <i>Frontiers in Immunology.</i></li>
                <li>Ascherio et al. (2022). "Longitudinal analysis reveals high prevalence of EBV associated with MS." <i>Science.</i></li>
                <li>Prusty et al. (2020). "Active HHV-6 infection of cerebellar Purkinje cells in tumors and autoimmune disease." <i>Journal of Medical Virology.</i></li>
                <li>Steere et al. (2020). "Lyme Arthritis: Mechanisms of Inflammation and Tissue Damage." <i>Nature Reviews Rheumatology.</i></li>
            </ul>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. | The C.A.L.M. Autoimmune Protocolâ„¢</p>
        </footer>
    </div>
</body>

</html>